Literature DB >> 17616582

Hot spots in prion protein for pathogenic conversion.

Kazuo Kuwata1, Noriyuki Nishida, Tomoharu Matsumoto, Yuji O Kamatari, Junji Hosokawa-Muto, Kota Kodama, Hironori K Nakamura, Kiminori Kimura, Makoto Kawasaki, Yuka Takakura, Susumu Shirabe, Jiro Takata, Yasufumi Kataoka, Shigeru Katamine.   

Abstract

Prion proteins are key molecules in transmissible spongiform encephalopathies (TSEs), but the precise mechanism of the conversion from the cellular form (PrP(C)) to the scrapie form (PrP(Sc)) is still unknown. Here we discovered a chemical chaperone to stabilize the PrP(C) conformation and identified the hot spots to stop the pathogenic conversion. We conducted in silico screening to find compounds that fitted into a "pocket" created by residues undergoing the conformational rearrangements between the native and the sparsely populated high-energy states (PrP*) and that directly bind to those residues. Forty-four selected compounds were tested in a TSE-infected cell culture model, among which one, 2-pyrrolidin-1-yl-N-[4-[4-(2-pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide, termed GN8, efficiently reduced PrP(Sc). Subsequently, administration of GN8 was found to prolong the survival of TSE-infected mice. Heteronuclear NMR and computer simulation showed that the specific binding sites are the A-S2 loop (N159) and the region from helix B (V189, T192, and K194) to B-C loop (E196), indicating that the intercalation of these distant regions (hot spots) hampers the pathogenic conversion process. Dynamics-based drug discovery strategy, demonstrated here focusing on the hot spots of PrP(C), will open the way to the development of novel anti-prion drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616582      PMCID: PMC1924567          DOI: 10.1073/pnas.0702671104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

2.  Rational discovery of novel nuclear hormone receptor antagonists.

Authors:  M Schapira; B M Raaka; H H Samuels; R Abagyan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation.

Authors:  K Doh-Ura; T Iwaki; B Caughey
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Mimicking dominant negative inhibition of prion replication through structure-based drug design.

Authors:  V Perrier; A C Wallace; K Kaneko; J Safar; S B Prusiner; F E Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

5.  Prion infection impairs the cellular response to oxidative stress.

Authors:  O Milhavet; H E McMahon; W Rachidi; N Nishida; S Katamine; A Mangé; M Arlotto; D Casanova; J Riondel; A Favier; S Lehmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

6.  Porphyrin and phthalocyanine antiscrapie compounds.

Authors:  S A Priola; A Raines; W S Caughey
Journal:  Science       Date:  2000-02-25       Impact factor: 47.728

7.  Effect of Congo red on wild-type and mutated prion proteins in cultured cells.

Authors:  O Milhavet; A Mangé; D Casanova; S Lehmann
Journal:  J Neurochem       Date:  2000-01       Impact factor: 5.372

8.  Elimination of prions by branched polyamines and implications for therapeutics.

Authors:  S Supattapone; H O Nguyen; F E Cohen; S B Prusiner; M R Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

9.  Identification of three novel mutations (E196K, V203I, E211Q) in the prion protein gene (PRNP) in inherited prion diseases with Creutzfeldt-Jakob disease phenotype.

Authors:  K Peoc'h; P Manivet; P Beaudry; F Attane; G Besson; D Hannequin; N Delasnerie-Lauprêtre; J L Laplanche
Journal:  Hum Mutat       Date:  2000-05       Impact factor: 4.878

10.  Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies.

Authors:  Kensuke Ishikawa; Yukitsuka Kudo; Noriyuki Nishida; Takahiro Suemoto; Tohru Sawada; Toru Iwaki; Katsumi Doh-ura
Journal:  J Neurochem       Date:  2006-10       Impact factor: 5.372

View more
  55 in total

1.  Proper calibration of ultrasonic power enabled the quantitative analysis of the ultrasonication-induced amyloid formation process.

Authors:  Kei-ichi Yamaguchi; Tomoharu Matsumoto; Kazuo Kuwata
Journal:  Protein Sci       Date:  2011-11-22       Impact factor: 6.725

2.  Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.

Authors:  Junji Hosokawa-Muto; Yuji O Kamatari; Hironori K Nakamura; Kazuo Kuwata
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

3.  Molecular docking of thiamine reveals similarity in binding properties between the prion protein and other thiamine-binding proteins.

Authors:  Nataraj S Pagadala; Trent C Bjorndahl; Nikolay Blinov; Andriy Kovalenko; David S Wishart
Journal:  J Mol Model       Date:  2013-10-15       Impact factor: 1.810

4.  Molecular motions in drug design: the coming age of the metadynamics method.

Authors:  Xevi Biarnés; Salvatore Bongarzone; Attilio Vittorio Vargiu; Paolo Carloni; Paolo Ruggerone
Journal:  J Comput Aided Mol Des       Date:  2011-02-17       Impact factor: 3.686

5.  Fragment molecular orbital calculations reveal that the E200K mutation markedly alters local structural stability in the human prion protein.

Authors:  Koji Hasegawa; Shirou Mohri; Takashi Yokoyama
Journal:  Prion       Date:  2010-01-04       Impact factor: 3.931

Review 6.  PrP assemblies: spotting the responsible regions in prion propagation.

Authors:  Stéphanie Prigent; Human Rezaei
Journal:  Prion       Date:  2011-04-01       Impact factor: 3.931

Review 7.  The therapeutic potential of chemical chaperones in protein folding diseases.

Authors:  Leonardo Cortez; Valerie Sim
Journal:  Prion       Date:  2014-05-12       Impact factor: 3.931

8.  Poly-L-histidine inhibits prion propagation in a prion-infected cell line.

Authors:  Ryo Honda; Kei-Ichi Yamaguchi; Abdelazim Elsayed Elhelaly; Mitsuhiko Fuji; Kazuo Kuwata
Journal:  Prion       Date:  2018-08-17       Impact factor: 3.931

9.  Helices 2 and 3 are the initiation sites in the PrP(C) → PrP(SC) transition.

Authors:  Jie Chen; D Thirumalai
Journal:  Biochemistry       Date:  2012-12-31       Impact factor: 3.162

10.  Establishment of a simple cell-based ELISA for the direct detection of abnormal isoform of prion protein from prion-infected cells without cell lysis and proteinase K treatment.

Authors:  Zhifu Shan; Takeshi Yamasaki; Akio Suzuki; Rie Hasebe; Motohiro Horiuchi
Journal:  Prion       Date:  2016-07-03       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.